Evidence map›Paper›PMID 41509268›Full record

ArticlebioRxiv : the preprint server for biology2025

HIV Nef amplifies mechanical heterogeneity to promote immune evasion.

Louise Leyre, Farah Mustapha, Alberto Herrera, Esther Lee, Emily Huntsman, Paul Zumbo, Jared Weiler, Parul Sinha, Ethan Naing, Connor Smith and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Louise LeyreInfectious Disease Division, Weill Cornell Medicine, New York, NY, USA.
Farah MustaphaImmunology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Alberto HerreraInfectious Disease Division, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0003-4189-9051
Esther LeeImmunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
Emily HuntsmanInfectious Disease Division, Weill Cornell Medicine, New York, NY, USA.
Paul ZumboApplied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.
Jared WeilerInfectious Disease Division, Weill Cornell Medicine, New York, NY, USA.
Parul SinhaInfectious Disease Division, Weill Cornell Medicine, New York, NY, USA.
Ethan NaingInfectious Disease Division, Weill Cornell Medicine, New York, NY, USA.
Connor SmithInfectious Disease Division, Weill Cornell Medicine, New York, NY, USA.
Colin KovacsMaple Leaf Medical Clinic and Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Canada.
Micheal GalianoMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nada WahmanMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Doron BetelApplied Bioinformatics Core, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-8006-7752
Kiera L ClaytonDepartment of Pathology, University of Massachusetts Chan Medical School, Worcester, MA, USA.
Morgan HuseImmunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, New York, NY, USA.
R Brad JonesInfectious Disease Division, Weill Cornell Medicine, New York, NY, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
REACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9M
ERASE HIV: Enterprise for Research and Advancements to Stop and Eradicate HIVUM1AI164562 · NIAID · EMORY UNIVERSITY · PI Deanna A Kulpa, Mirko Paiardini · 2021 to 2026
$30.0M
Immunologic control of HIV-1 through combination bNAbs and biologics.U01AI145921 · NIAID · ROCKEFELLER UNIVERSITY · PI CASKEY, MARINA · 2019 to 2024
$8.5M
Synaptic Control of Cytotoxic T cell FunctionR01AI087644 · NIAID · SLOAN-KETTERING INST CAN RESEARCH · PI HUSE, MORGAN A · 2010 to 2025
$7.3M
Impact of IL-15 immunotherapy on tissue-specific CD8 T cells to reduce the CNS HIV reservoir seeding and persistenceR01MH130197 · NIMH · OREGON HEALTH & SCIENCE UNIVERSITY · PI Lishomwa C Ndhlovu, Afamefuna Okoye · 2022 to 2026
$5.1M
Targeting HIV-specific T cell differentiation programs to enhance post-treatment control of HIVR01AI170239 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Rachel Lena Rutishauser · 2022 to 2026
$4.0M
Targeted delivery of cytopathicity enhancing agents, and co-ordination with shock and kill, to reduce HIV reservoirsR01AI147845 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI IRVINE, DARRELL J, JONES, R. BRAD · 2019 to 2023
$4.0M
Understanding Immune Evasion by HIV-1 RepliclonesR01AI165031 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI HALVAS, ELIAS K. · 2021 to 2025
$3.6M
Enhancing Susceptibility of HIV Reservoirs to CTL Through a Discovery to Translational ApproachR01AI176601 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI R. Brad Jones, Neville Sanjana · 2023 to 2026
$3.3M
Deciphering Mechanisms of HIV Latency Reversal in Perinatal InfectionsR01AI150412 · NIAID · JOHNS HOPKINS UNIVERSITY · PI PERSAUD, DEBORAH · 2020 to 2023
$3.1M
Mechanisms of CTL Resistance in HIV ReservoirsR01AI170245 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI JONES, R. BRAD · 2022 to 2025
$3.0M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA008748NIAID NIH HHS F31 AI191953NIAID NIH HHS R01 AI087644NIAID NIH HHS R01 AI147845NIAID NIH HHS R01 AI150412NIAID NIH HHS R01 AI165031NIAID NIH HHS R01 AI167691NIAID NIH HHS R01 AI170239NIAID NIH HHS R01 AI170245NIAID NIH HHS R01 AI176601NIAID NIH HHS R01 AI176943NIAID NIH HHS R21 AI170246NIAID NIH HHS R21 AI172554NIAID NIH HHS R37 AI181626NIAID NIH HHS U01 AI145921NIAID NIH HHS UM1 AI164562NIAID NIH HHS UM1 AI164565NIMH NIH HHS R01 MH130197
6 · The paper itself

Abstract

Intracellular pathogens must evade cytotoxic immunity to establish persistent infection. Although immune escape is typically viewed through a biochemical lens, the ability of certain pathogens to alter the mechanical properties of infected cells suggests that biophysical mechanisms may also contribute to the process. Here, we show that a subset of CD4

Identifiers

PMID41509268
PMCPMC12776059

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.